Physicians' Academy for Cardiovascular Education

CV benefit of PCSK9 inhibitor is consistent regardless of inflammation level

Inflammatory and Cholesterol Risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk)

Literature - Bohula EA, Giugliano RP, Leiter LA, et al. - Circulation 2018;137, and simultaneously presented at ACC.18 in Orlando, FL, USA

Introduction and methods

The prognostic value of LDL-c and high-sensitivity C-reactive protein (hsCRP) has been established, but not in the setting of extremely low LDL-c [1-3]. In this analysis of the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) trial, the consistency of benefit of the PCSK9 inhibitor evolocumab for the prevention of cardiovascular (CV) events by baseline hsCRP was assessed. In addition, the importance of inflammatory and residual cholesterol risk as defined by LDL-c and hsCRP levels was evaluated.

FOURIER was a randomized, double-blind placebo-controlled trial that enrolled 27,564 patients aged 40 to 85 years with clinically evident, stable atherosclerotic CV disease and additional risk factors [4,5]. Eligible patients had LDL-c ≥70 mg/dL or non–HDL-c ≥100 mg/dL while taking an optimized regimen of lipid-lowering therapy (at least atorvastatin 20 mg daily or its equivalent, with or without ezetimibe).

Patients were randomly assigned to subcutaneous evolocumab (either 140 mg Q2W or 420 mg Q4W) or matching placebo injections, and were followed for a median of 2.2 years (IQ: 1.8–2.5 years). The primary efficacy endpoint was a composite of CV death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary endpoint was a composite of CV death, MI, or stroke.

For this analysis, endpoints were compared across strata of baseline hsCRP (<1, 1–3, and >3 mg/dL), and assessed across values for baseline hsCRP and LDL-c achieved at 1-month in the entire trial population.

Main results

Conclusion

LDL-c reduction with evolocumab decreases CV events across hsCRP strata in FOURIER with greater absolute risk reductions in patients with higher baseline hsCRP. Adverse CV event rates were independently associated with both LDL-c and hsCRP, which was a risk predictor even in patients with very low levels of LDL-c. These results support the importance of inflammatory and residual cholesterol risk.

References

Show references

Download the slide Find this article online at Circulation

Click to view slide